ALXO
Income statement / Annual
Last year (2024), ALX Oncology Holdings Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, ALX Oncology Holdings Inc.'s net income was -$134.85 M.
See ALX Oncology Holdings Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$1.18 M |
$4.80 M |
$2.07 M |
| Cost of Revenue |
$0.00
|
$836,000.00
|
$1.47 M
|
$736,000.00
|
$1.08 M
|
$4.36 M
|
$1.88 M
|
| Gross Profit |
$0.00
|
-$836,000.00
|
-$1.47 M
|
-$736,000.00
|
$107,000.00
|
$436,000.00
|
$187,000.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0.09
|
0.09
|
0.09
|
| Research and Development Expenses |
$116.37 M
|
$141.80 M
|
$98.40 M
|
$60.17 M
|
$28.96 M
|
$16.31 M
|
$11.27 M
|
| General & Administrative Expenses |
$26.09 M
|
$28.48 M
|
$29.04 M
|
$23.39 M
|
$14.81 M
|
$3.31 M
|
$2.60 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$26.09 M
|
$28.48 M
|
$29.04 M
|
$23.39 M
|
$14.81 M
|
$3.31 M
|
$2.60 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$260,000.00
|
$84,000.00
|
-$404,000.00
|
-$5,000.00
|
-$2,000.00
|
| Operating Expenses |
$142.47 M
|
$170.28 M
|
$127.44 M
|
$83.56 M
|
$43.77 M
|
$19.62 M
|
$13.87 M
|
| Cost And Expenses |
$142.47 M
|
$170.28 M
|
$127.44 M
|
$83.56 M
|
$44.85 M
|
$23.98 M
|
$15.75 M
|
| Interest Income |
$9.37 M
|
$10.65 M
|
$4.04 M
|
$91.00
|
$124,000.00
|
$21.00
|
$0.00
|
| Interest Expense |
$1.73 M
|
$1.57 M
|
$0.00
|
$13,000.00
|
$811,000.00
|
$21,000.00
|
$0.00
|
| Depreciation & Amortization |
$872,000.00
|
$836,000.00
|
$1.47 M
|
$736,000.00
|
$202,000.00
|
$429,000.00
|
$431,000.00
|
| EBITDA |
-$132.25 M |
-$158.40 M |
-$121.95 M |
-$83.47 M |
-$43.46 M |
-$18.76 M |
-$13.26 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
-37.28
|
-3.91
|
-6.41
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
-36.94
|
-4
|
-6.62
|
| Total Other Income/Expenses Net |
$7.62 M
|
$9.47 M
|
$4.02 M
|
$71,000.00
|
-$1.84 M
|
-$26,000.00
|
-$2,000.00
|
| Income Before Tax |
-$134.85 M
|
-$160.81 M
|
-$123.42 M
|
-$83.48 M
|
-$45.50 M
|
-$19.21 M
|
-$13.69 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
-38.49
|
-4.01
|
-6.62
|
| Income Tax Expense |
$0.00
|
$0.00
|
$64,000.00
|
-$21,000.00
|
$241,000.00
|
$34,000.00
|
$45,000.00
|
| Net Income |
-$134.85 M
|
-$160.81 M
|
-$123.48 M
|
-$83.46 M
|
-$45.74 M
|
-$19.24 M
|
-$13.73 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
-38.7
|
-4.01
|
-6.64
|
| EPS |
-2.58 |
-3.74 |
-3.03 |
-2.07 |
-1.15 |
-0.53 |
-0.63 |
| EPS Diluted |
-2.58 |
-3.74 |
-3.03 |
-2.07 |
-1.15 |
-0.53 |
-0.63 |
| Weighted Average Shares Out |
$52.17 M
|
$42.99 M
|
$40.70 M
|
$40.31 M
|
$39.84 M
|
$36.49 M
|
$21.95 M
|
| Weighted Average Shares Out Diluted |
$52.17 M
|
$42.99 M
|
$40.70 M
|
$40.31 M
|
$39.84 M
|
$36.49 M
|
$21.95 M
|
| Link |
|
|
|
|
|
|
|
